Hai Tran, MD
Pulmonary Disease · New Orleans, LANPI 1407350267
Payments from drug & device makers
What this record shows
This record is dominated by education: $2,526 of the $3,778 with a category attached, or 66.8%. Intuitive Surgical accounts for 83.9% of it on its own, with 7 other manufacturers making up the rest. 2025 is the largest year on record at $3,463, more than ten times the $25 reported in 2022. That places this record below the midpoint for pulmonary disease clinicians in LA, where the typical reported total is $3,696.
Across 30 payments — averaging $125.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$3K
- Actelion Pharmaceuticals US, Inc.$290
- United Therapeutics Corporation$133
- Sanofi$75
- Merck$45
- Bayer$26
- plus $40 from 2 others
What the payments were for
- Travel & lodging$54214%
- Food & beverage$71119%
- Education$2,52667%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 9 | $3,169 |
| Actelion Pharmaceuticals US, Inc. | 7 | $290 |
| United Therapeutics Corporation | 6 | $133 |
| Sanofi | 3 | $75 |
| Merck | 2 | $45 |
| Bayer | 1 | $26 |
| Regeneron Healthcare Solutions, Inc. | 1 | $24 |
| KCI USA, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$3,084
- UPTRAVI$123
- OPSUMIT$123
How this compares
$3,778 in reported general payments places this provider in the 50th percentile of 189 pulmonary disease providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 12 | $47,540 |
| Spiriva HandihalerTiotropium Bromide | 16 | $19,770 |
| Incruse ElliptaUmeclidinium Bromide | 12 | $6,329 |
| Wixela InhubFluticasone Propion/Salmeterol | 11 | $1,291 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 32 | $1,006 |
| Fluticasone Propionate | 20 | $255 |
| Montelukast Sodium | 22 | $116 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in New Orleans
- Joseph LaskyNew Orleans$447K
- Ramsy AbdelghaniNew Orleans$308K
- Juzar AliNew Orleans$216K
- Nicole LapinelNew Orleans$140K
- Courtney ShappleyNew Orleans$66K
- Susan GunnNew Orleans$28K
- David PattenNew Orleans$12K
- Yasin KhanNew Orleans$12K
- Ross KlingsbergNew Orleans$11K
- Nereida ParadaNew Orleans$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.